© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Asthma
American Academy of Family Physicians Awarded $31 Million for Comparative Asthma Treatment Study
August 01, 2022
The Patient-Centered Outcomes Research Institute (PCORI) has approved an award for the American Academy of Family Physicians (AAFP) of $31 million to fund a large comparative study of asthma treatments.
Fluctuations in Sex Hormones May Drive Asthma Symptoms in Women
July 15, 2022
Asthma becomes more prevalent in females than males in puberty. Researchers have hypothesized that sex hormones may play a significant role in the manifestation of asthma symptoms.
A Surge of Biologics for Severe Asthma
June 21, 2022
Six biologics are on the market and more are in the pipeline. Biologics target the inflammatory cytokines involved in the pathogenesis of asthma.
An Upstream Strategy for Treating Severe Asthma
June 17, 2022
Thymic stromal lymphopoietin (TSLP) has been identified as starting the cascades of cytokines that result in the inflammation that underlies many cases of severe asthma. A review paper discusses how Tezspire inhibits TSLP and the evidence for its safety and efficacy in numerous clinical trials.
IL-13 in People with Allergic Asthma May Offer Some Protection Against Severe COVID
June 14, 2022
University of North Carolina researchers report that interleukin-13, responsible for inflammation and severe asthma symptoms, may have properties that fend off the SARS-CoV-2 virus that causes COVID-19.
Follow-up Care Helps Prevent Repeat Asthma-Related Emergency Department Visits in Children and Young Adults
June 13, 2022
But researchers find that fewer than 1 in 4 children and young adults had follow-up visits.
Medicaid Covers Nonmedical Services as Part of Initiative to Address Social Determinants of Health
June 10, 2022
California’s “in lieu of services” (ILOS) program includes asthma remediation services such as dehumidifiers, improved ventilation and mold removal.
New Target Discovered for Non-Type 2 Inflammation in Severe Asthma
May 17, 2022
Genentech researchers identify oncostatin M as a protein that may be responsible for the severe airway inflammation seen in patients with noneosinophilic asthma.
Dupixent Improves Severe Asthma Symptoms in a Real-World Setting, but Switching May Require Eosinophil Monitoring
May 16, 2022
Real-world study conducted in Japan shows Dupixent (dupilumab) reduced the number of annual severe asthma exacerbations by 53%. There were some reports of adverse events associated with high eosinophil levels in patients who switched to Dupixent after taking a different biologic.
Several Biologics To Treat Severe Asthma Can Be Self-Administered at Home — Patients Prefer It
May 12, 2022
Xolair (omalizumab), Fasenra (benralizumab), Dupixent (dupilumab) and Nucala (mepolizumab) can now be self-administered.